公告内容

三项新拨款使有前途的计划不断向前发展

2017年11月14日

类别:新赠款

The 老年痴呆症’药物发现基金会(ADDF)宣布了三笔新的投资,所有这些投资都是ADDF先前资助的计划。 Two of the awards support novel drugs designed to reduce brain 炎 and the third is for the development of a screening tool to detect early 老年痴呆症’s disease.

ADDF的创始执行董事兼首席科学官Howard Fillit博士说:“Our goal is to continue funding successful programs, and we are pleased that these researchers are forging ahead with promising novel drugs and a potential new blood test for 老年痴呆症’s.” 

治疗方法
临床前

D. Martin Watterson,NeuroKine Therapeutics,LLC博士
将p38aMAPKI候选药物MW150催化入临床
$ 150,000
Inflammation in the brain can damage neurons and accelerate the progression of 老年痴呆症’s disease. And kinases, which are enzymes that perform a range of critical functions in our bodies, are involved in brain 炎. With funding from the ADDF that began in 2001, Dr. Watterson worked to discover a molecule that would target 炎 in the brain and slow 老年痴呆症’的疾病。他最终开发了MW150,一种抑制特定激酶并减少脑部炎症的药物。现在,他和他的团队,包括哥伦比亚大学的Arancio博士,将完成必要的最后一组研究,以汇编并向FDA提交研究用新药(IND)申请,以批准进行人体临床试验。目标是在获得批准后立即启动1期试验。 

Alexandros Makriyannis,东北大学博士学位
FAAH Inhibitors as 老年痴呆症'疾病药物
$ 250,000
Cannabinoid receptors in the brain are involved in immune response and 炎. With ADDF funding in 2015, Dr. Makriyannis and his team began developing novel 老年痴呆症’s drugs that indirectly target the cannabinoid receptors. He aims to activate the CB1 cannabinoid receptor by inhibiting an enzyme called Fatty Acid Amide Hydrolase (FAAH). In this proposal, Dr. Makriyannis and team will design novel FAAH inhibitors that prevent damage to neurons and synapses induced by 老年痴呆症’的疾病。如果成功,这项工作将使这些有前途的候选药物更接近人体临床测试。

生物标记

Blaine Roberts,弗洛里神经科学与心理健康研究所博士
血浆Abeta蛋白复合物用于早期检测脑淀粉样蛋白积累
$ 149,518
老年痴呆症’s remains a difficult disease to accurately diagnose, because there are few tests available. Dr. Roberts is developing a screening tool for the early detection of 老年痴呆症’s, before symptoms emerge. With previous ADDF funding, Dr. Roberts and his colleagues discovered protein complexes in the blood that have the potential to provide an early diagnosis of 老年痴呆症’的疾病。 ADDF的新资金将帮助罗伯茨博士’s group to optimize two different methods that can more quickly and sensitively measure these protein complexes. They will use samples from the Australian Imaging and Biomarker Lifestyle (AIBL) study of aging, one of the largest studies of 老年痴呆症’s disease in the world, to validate their new analytical methods. The goal is to create an affordable blood test to detect 老年痴呆症’处于早期阶段。